1.00Open1.00Pre Close0 Volume610 Open Interest200.00Strike Price0.00Turnover63.57%IV15.06%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry1.00Extrinsic Value100Contract SizeAmericanOptions Type-0.0773Delta0.0053Gamma234.28Leverage Ratio-0.1557Theta-0.0060Rho-18.10Eff Leverage0.0624Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet